Entospletinib

featured

WARNING: This product is for research use only, not for human or veterinary use.

Description:Entospletinib, also known as GS-9973, is a highly selective and orally efficacious Syk inhibitor which is currently undergoing clinical evaluation for autoimmune and oncology indications. In Phase II clinical trials, Entospletinib demonstrates clinical activity in subjects with relapsed or refractory CLL with acceptable toxicity.

Price and Availability

Entospletinib, purity > 98%, is in stock. The same day shipping out after order is received.

Chemical Structure

Theoretical Analysis

MedKoo Cat#: 206107Name: EntospletinibCAS#: 1229208-44-9Chemical Formula: C23H21N7OExact Mass: 411.18076Molecular Weight: 411.46Elemental Analysis: C, 67.14; H, 5.14; N, 23.83; O, 3.89

Synonym:Entospletinib; GS9973; GS 9973; GS-9973.

IUPAC/Chemical Name:6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine

InChi Key:XSMSNFMDVXXHGJ-UHFFFAOYSA-N

InChi Code:InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27)

SMILES Code:C12=NC=CN1C=C(C3=CC4=C(C=C3)C=NN4)N=C2NC5=CC=C(N6CCOCC6)C=C5

Technical Data

Additional Information

References

1: Sharman J, Hawkins M, Kolibaba K, Boxer M, KleinL, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial ofentospletinib (GS-9973), a selective  spleen tyrosine kinaseinhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr9;125(15):2336-43. doi: 10.1182/blood-2014-08-595934. Epub 2015 Feb 18.PubMed PMID: 25696919; PubMed Central PMCID: PMC4401348.